KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Change in Receivables (2020 - 2025)

Boston Scientific (BSX) has disclosed Change in Receivables for 6 consecutive years, with $98.0 million as the latest value for Q4 2025.

  • Quarterly Change in Receivables rose 8.89% to $98.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $269.0 million through Dec 2025, down 23.36% year-over-year, with the annual reading at $269.0 million for FY2025, 23.36% down from the prior year.
  • Change in Receivables hit $98.0 million in Q4 2025 for Boston Scientific, up from $32.0 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $148.0 million in Q4 2021 to a low of -$14.0 million in Q3 2021.
  • Historically, Change in Receivables has averaged $67.8 million across 5 years, with a median of $74.5 million in 2023.
  • Biggest five-year swings in Change in Receivables: plummeted 111.38% in 2021 and later soared 1000.0% in 2024.
  • Year by year, Change in Receivables stood at $148.0 million in 2021, then crashed by 70.27% to $44.0 million in 2022, then soared by 68.18% to $74.0 million in 2023, then grew by 21.62% to $90.0 million in 2024, then increased by 8.89% to $98.0 million in 2025.
  • Business Quant data shows Change in Receivables for BSX at $98.0 million in Q4 2025, $32.0 million in Q3 2025, and $32.0 million in Q2 2025.